Cortexin vs TRH

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Hypothalamic tripeptide (pGlu-His-Pro-NH2); binds TRH-R1/R2; stimulates TSH/prolactin release; direct CNS effects independent of thyroid axis including synaptic potentiation

Thyrotropin-releasing hormone (TRH) is a hypothalamic tripeptide that serves as the primary regulator of TSH secretion from the pituitary gland but is also widely distributed throughout the CNS as an independent neuromodulator affecting dopaminergic, cholinergic, and serotonergic neurotransmitter systems independent of its thyroid axis role. Beyond endocrine function, centrally administered TRH exerts arousal-promoting effects and has been shown in preclinical models to prevent depletion of cortical acetylcholine and monoamines following brain injury, suggesting a neuroprotective neuromodulatory role. Controlled human research has demonstrated that TRH attenuates scopolamine-induced memory impairment, consistent with its proposed role in potentiating cholinergic signaling and providing direct evidence for central cognitive effects of the parent compound. TRH is used clinically as a diagnostic agent (protirelin) for thyroid function testing; as a cognitive or neuroprotective agent it remains investigational, with no approved indication for these uses and human evidence limited to small mechanistic studies. TRH in neuroendocrinology and nootropic research Beyond its role as a hypophysiotropic releasing factor, TRH functions as a neuromodulator throughout the CNS. TRH receptors (TRH-R1 and TRH-R2) are expressed in the cerebral cortex, hippocampus, limbic system, and spinal cord, mediating effects on arousal, mood, and locomotor activity independent of the pituitary-thyroid axis. Animal studies document TRH's analeptic properties — the peptide can rapidly reverse sedation from barbiturates, ethanol, and opioids, suggesting a direct CNS excitatory role. This arousal-promoting effect has attracted research interest in fatigue, cognitive impairment, and as an emergency reversal agent in overdose contexts, though clinical translation has been limited by TRH's very short half-life (approximately 5 minutes in plasma due to rapid enzymatic degradation). Taltirelin (TA-0910), a more metabolically stable TRH analogue, is approved in Japan for spinocerebellar degeneration — the only approved clinical application in this research space. The TRH stimulation test (200–500mcg IV bolus with serial TSH/prolactin sampling) has been used diagnostically, though modern ultrasensitive TSH assays have largely replaced it. Exogenous TRH for nootropic or energy applications is available as a research peptide; intranasal delivery to bypass peripheral degradation has been explored in preclinical work.